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PREFACE 
This study uses the channel catfish as a poikilother-
mic model with which the pharmacokinetics of the aminogly-
coside antibiotic, gentamicin, could be studied. The 
primary objectives of this study are to establish reliable 
pharmacokinetic parameters on which a rational course of 
antibiotic therapy can be based and to determine the 
effectiveness and reliability of selected enteral and 
parenteral routes of administration. 
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deepest gratitude .to Dr. Lester L. Rolf. Without his 
incredibly patient and generous support, this thesis 
could never have been completed. Thanks are also extended 
to Dr. George Burrows for his counsel and financial sup-
port, to Dr. James Blankemeyer for many late hours of com-
puter programming work, to Dr. Bruce Lessley and Dr. James 
Breazile for their assistance in ironing out those nasty 
little academic quandries that tend to crop up with 
investigations into new areas of study, to Ms. Laverne 
Jones for her indispensable assistance with the literature 
search, to Ms. Mary Bober and Dr. Jim Walker for the 
contribution of important journal articles and to Dr. 
Subbiah Sangiah for his advice and moral support. 
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Antibiotics in Teleosts 
The United States Food and Drug Administration has 
approved only salt, acetic acid and sulfamerazine for use 
in all food fishes and oxytetracycline for restricted use 
' d ' h 1 in trout, salmon an catfis • No antibiotics are 
specifically marketed for fish species not intended for 
human consumption, but regulation of antibiotic use in 
' h ' 'd d 112 'd these fis es is not wi esprea • Sulfonami es, tetra-
cyclines, chloramphenicol, erythromycin and various 
aminoglycosides have been recommended as antibiotics of 
value in the treatment of tank water for non-food 
' 2,3 d ' fishes. In the absence of controlle experimental 
data on the pharmacology of antibiotics in fish, case 
study and personal experience have frequently been the 
basis for drug therapy. It has recently been shown that 
some antibiotics once thought to be well absorbed fol-
lowing enteral administration are not(e.g. chloramphenicol 
in channel catfish), while others previously considered to 
be of little use in water treatment may actually be of 
therapeutic value (e.g. kanamycin in channel catfish). 415 
1 
2 
Aeromonas, Vibrio and Pseudomonas are the principal 
h . b . . . h 3,4 genera of pat ogenic acteria affecting fis • Other 
gram negative bacteria considered important in aquaculture 
H h . c b . 2. . 3 are emop ilus, oryne acterium , Myxobacteria , and 
Edwardsiella6 • To combat infections caused by these path-
ogens, antibiotics are commonly administered by way of 
water treatment or medicated feed. 2 ' 3 These methods of 
administration present two important problems. First, it 
is difficult to regulate dosage since an antibiotic added 
to water may not become evenly distributed throughout a 
tank or pond and medicated feed may be consumed by healthy 
fish to excess while diseased, anorectic individuals 
remain untreated. Second, the extensive use of an anti-
biotic armamentarium including only two bacteriostatic 
drugs would greatly increase the probability that resis-
tant strains of bacterial pathogens would develop. 11617 
The use of a broader range of antibiotics and the use 
of bactericidal agents has been suggested to aid in the 
prevention of resistant bacterial strain development. 3 
Use of parenteral routes of drug administration further. 
reduces the probability of resistant strain development by 
reducing the likelihood that potentially pathogenic bac-
teria in the environment would be exposed to sublethal 
amounts of antibiotic. Parenteral medication allows 
accurate and selective dosage of a therapeutic agent and 
is best suited for valuable breeding, aquarium or experi-
. h 2 mental f is • The aminoglycoside antibiotic, gentamicin, 
is known to be bacterial to the three principal genera of 
bacterial fish pathogens as well as other less conunonly 
5 8 9 
encountered gram negative pathogens. ' ' Gentamicin's 
broad spectrum of activity against gram negative bacteria 
3 
should render it an antibiotic of great potential value in 
aquaculture. 
Gentamicin Pharmacology 
The aminoglycoside antibiotic, gentamicin, was first 
described in 1963. 10 It is derived from the actinomycete 
Micromonospora purpurea and is actually a complex or fam-
9 ily of closely related compounds. The primary components 
of the gentamicin family are gentamicins c1 , Cla' and c2 • 
These gentamicins are aminoglycosidic aminocyclitols con-
sisting of two amino sugars joined in glycosidic linkage 
2 d ' ( ' 1) 11 to a - eoxystreptamine nucleus see Figure • They 
are weak organic bases with pKa's of approximately 7.812 
and are very similar in biological activity. 13 
Gentamicin is considered to be completely bioavail-
able in mammals when administered intravenously or intra-
12 
muscularly, but is not absorbed in significant amounts 
h ' ' 9,13 ' h d w en given orally in manunals or fis . Bloo concen-
trations of the drug after parenteral administration are 
highly variable and are not dependably predictable from 
dosages based on body weight in 14,15,16 man. Calculation 
of dose by lean body weight has been proposed as a more 
dependable estimator of a dosage that will correspond to 
4 
plasma drug concentration in a patient with normal renal 
function, since aminoglycoside~ are minimally distributed 
. ft . 17 in a ty tissue. Packed cell volume has also been shown 
to affect peak serum levels of gentamicin by 2 g/ml for 
h f . . t t h . h t . 16 eac ive poin s percen age c ange in ema ocrit. 
H H 
H 
0 
OH 
2-deogystreptamine 
Gentamicin c1 : R1 ,R2 = CH3 • Gentamicin c1 a: R1 ,R2 = H 
Gentamicin c2 : Rl = CH3 , R2 = H 
Figure 1. Structures of the Three Primary Components of 
the Gentamicin Complex. 
Studies in mammals indicate that the kinetics of gen-
tamicin are consistent with a two-compartmen~ pharmaco-
ki. neti· c model. 18 ' 19 B f · t 1 t t l ecause o i s po ar na ure a norma 
body pH's, gentamicin is largely excluded from most 
cells, 13 but is distributed throughout the extracellular 
fluids of body tissues16 other than the central nervous 
13,18 
system and eye. Gentamicin is not significanlty pro-
tein bound20 and is excreted predominately by glomerular 
filtration16117118 in an unmetabolized form. While some 
drug is eliminated through the biliary system, it is 
5 
'd ' ' 9 consi ered a minor route of excretion. The serum half-
life of gentamicin ranges from 1.3-3.6 hours in man, 23 1.8 
17 24 hours in ewes, 3 hours in calves, 2.2-2.9 hours in 
19 0 25 horses and 82 hours at 24 C in gopher snakes • 
Gentamicin has been shown to cause nephrotoxicity, 
ototoxicity and neuromuscular blockade in mammals. Amino-
glycoside concentration in the renal cortex is markedly 
higher than plasma concentrations. 21 Excessive drug con-
centration in the renal cortex can cause acute tubular 
13 
necrosis with secondary interstitial damage. These de-
generative changes seem to be associated with peak blood 
concentrations of gentamicin (i.e. greater than 2 ,Mg/ml) 
and the total time of renal exposure to this antibiotic. 14 
Trough serum concentrations of gentamicin that consis-
tently exceed 2,,..ug/ml are also believed to be related to 
the incidence of ototoxicity. 13 There is a linear rela-
tionship between dosage of gentamicin and drug concentra-
tion in the endolymph and perilymph. 26 With protracted 
gentamicin therapy, endolymph and perilymph drug concen-
trations are many times greater than gentamicin levels in 
the blood. The ototoxic process involves alteration of 
normal sodium and potassium transport in the spiral liga-
ment and stria vascularis which in turn causes damage to 
27 the sensory cells of the spiral organ. The mechanisms 
by which gentamicin elicits its ototoxic and nephrotoxic 
effects are thought to be closely related. 
6 
The effects gentamicin has on muscle tissue seem to 
be produced through mechanisms not related to those 
causing nephrotoxicity and ototoxicity. Aminoglycosides 
have been shown to inhibit presynaptic release of acetyl-
choline and reduce postsynaptic sensitivity to acetylcho-
line, 28 resulting in neuromuscular blockade that is rever-
sible by the administration of a calcium salt. 13 Gentami-
cin has also been shown to have a dir~ct myolitic effect 
h h h b . . 29 d on t e smoot muscle of t e il1ary tract an ureters of 
. 30 the urinary tract. 
Mechanism of Antibacterial Action and 
Bacterial Resistance to Gentamicin 
Most of the work done on the mechanism of action of 
aminoglycoside antibiotics has been done on streptomycin. 
Because of this, this discussion of mechanisms of action 
will deal mainly with aminoglycosides as a group using 
streptomycin as a model, rather than with gentamicin 
specifically. 
Aminoglycosides are rapidly bactericidal and act 
directly on bacterial ribosomes where they bind to the 30S 
and SOS ribosomal subunit, 30 cause formation of afunc-
tional initiation complexes 31 and induce misreading of the 
32 bacterial mRNA templates • In order to reach the bac-
terial ribosomes, the large, polar aminoglycoside mole-
cules must first be transported across the cell membrane. 
A biphasic model of transport of streptomycin and gentami-
7 
cin across bacterial cell membranes was proposed by Bryan 
and Van Den Elzen in 1977. 33 According to this model, the 
energy dependent phase I begins with low-affinity, diva-
lent cation inhibited, binding of aminoglycodie molecules 
to portions of respiratory energization complexes that are 
transported across the cell membrane. Once across the 
cell membrane, the aminoglycosides bind with ribosomes 
associated with the membrane, triggering the energy depen-
dent phase II transport. Phase II is associated with 
functional or architectural changes in the membrane that 
result in rapid influx of aminoglycoside and correspond 
with the onset of the inhibition of protein synthesis. 
The presence of other antibiotics that alter the structure 
of the cell wall (e.g. penicillin) act synergistically 
with the aminoglycosides by markedly accelerating their 
movement into the bacterial cells. 34 Since movement of 
aminoglycoside molecules across bacterial cell membranes 
is dependent on the presence of cell membrane complexes 
associated with aerobic metabolism, anaerobic bacteria are 
. h 'b' . 13,35 usually resistant to t ese anti iotics. Other mech-
anisms of resistance include ribosomal mutation, a rela-
36 tively rare phenomenon, and the development of adenyly-
lating, acetylating and/or phosphorylating enzymes in the 
bacterial cell membrane at or near aminoglycoside binding 
. 13 
sites. 
Novokhatskii and Gerasimova 37 demonstrated that, at a 
concentration of 10 mg/ml, gentamicin inhibited the 
8 
cytoplasmic replication of Venezuelan Equine Encephalitis 
and Sindbis RNA viruses growing in chick embryon fibro-
blasts (CEF) without observable impairment of cell viabi-
lity. The primary trypsinized CEF cultures' capacities 
for production of high titers of the model viruses were 
reduced after 24 hours of culture growth post gentamicin 
treatment and removal. Others have found that gentamicin 
at 100)-!g/ml to 200,,Ug/ml levels effectively inhibit viral 
replication in tissue cell cultures. 38 Gentamicin's anti-
viral activity is presumably related to its ability to 
interfere with the intracytoplasmic ribosomal activity 
required for viral replication. 
The antibacterial action of gentamicin is greatest at 
an alkali'ne pH. 39140 It l' · l · · ·1 s c inica use is primari y 
d . d d b' . b . 8,13 irecte towar s aero ic gram negative acteria, 
although some species of gram positive bacteria are also 
'b 8 suscepti le • The adverse effect of an acid pH on genta-
. . 40 . . . h' micin is a feature of potential importance for t is 
antibiotic in channel catfish. It has been shown that the 
pH of the catfish's body fluids (at 26°c blood pH= 7.75 
and intracellular fluid pH= 7.35) become less alkaline as 
. b d . 41 its o y temperature increases at a rate of 0.018 pH 
· 10 42 units per C change in temperature Cardiovascular 
changes associated with increased body temperature may 
also shift plasma gentamicin to other body-fluid compart-
. 43 
ments. This compartmental shift would result in reduced 
9 
blood concentration of the drug and increased apparent 
volume of the central compartment. 
Renal Physiology and Circulatory Anatomy 
The nephron of Ictalurus punctatus is representative 
of freshwater teleosts. It consists of a well developed 
glomerulus and Bowman's capsule, a neck segment of cili-
ated cuboidal epithelium, first and second proximal seg~ 
ments lined with cuboidal epithelium, an intermediate 
segment histologically similar to the neck segment, a dis-
tal tubule, and collecting tubule and duct. 44 The urinary 
bladder appears to function as a part of the nephron by 
selectively absorbing ions and water. The kidneys func-
tion primarily to excrete excess water while retaining 
most of the filtered solutes. 45 Secondarily, the kidneys 
supplement the gills' pH regulating activity and nroduce 
41 an alkaline urine (pH= 7.4 ± 0.18). 
The kidneys of the channel catfish are completely 
separated into cranial and caudal portions ref erred to as 
the head kidneys and trunk kidney, respectively. The 
renal corpuscles and convoluted tubules present in the 
head kidneys of juveniles less than four centimeters in 
total body length (TL), completely degenerate by the time 
the juvenile catfish reach four centimeters TL. The head 
kidneys of channel catfish greater than four centimeters 
TL are composed entirely of endocrine and hemopoietic 
tissue. The caudal kidney segments are fused caudally to 
10 
form a single Y-shaped mass known as the trunk kidney. 
Corpuscles of Stannius are located on the lateral margins 
of the trunk kidney and are thought to be associated with 
osmoregulation, steroid production or storage, renin pro-
. . b . 44 duction and the regulation of calcium meta olism. Some 
hemopoietic tissue, similar to that found in the head kid-
neys is found in the trunk kidney. The head and trunk 
kidneys' arterial supply branches directly from the dorsal 
aorta. The trunk kidney also receives blood from the 
caudal vein. Efferent blood leaves the trunk kidney by 
way of the caudal cardinal veins, which deliver blood 
directly to the head kidneys. The head kidneys are 
drained by the common cardinal veins leading to the heart. 
A schematic diagram of the channel catfish circulatory 
44 system taken from Grizzle and Rogers is illustrated in 
Figure 2. 
The major determinant of urine flow is glomerular 
filtration rate (GFR). GFR is altered by arginine vasoto-
cin, angiotensin and cortisol through their influences on 
systemic blood pressure and blood flow and/or their effect 
h . . . h 45 ( . on t e population of functioning nep rons see Figure 
3). The GFR is largely unaffected by stressful events 
41 such as handling and surgery. 
HEAD 
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Grizzle, J.M. and Rogers, W. A.: Anatomy and Histology .of the Channel Catfish. 
Department of Fisheries and Allied Aquacultures, Auburn University Agricul-
tural Experiment Station. Auburn, Alabama: Auburn Printing, Inc., 1976. 
Figure 2. A Diagram of the Major Arteries and Veins of the Channel Catfish. 
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f---' 
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------------------------
Glomerulus 
----------------------- Neck Segment 
~·a-____________ Proximal Segment I 
H;_o 
11,,~c1-
11J.o 
-------------~ o 
Proximal Segment II 
--------------------- Distal Tubule 
-------------------
Collecting Tubule 
:·~------------------- Collecting Duct 
----------------------------
Urinary Bladder 
Solid and open arrows indicate active and passive move-
ments, respectively. Broken arrows indicate low per-
meability to water. U-shaped arrows indicate possible 
Na+ and c1- cotransport. Question marks indicate sites 
of action that are likely, but unproven. 
Source: Nishimura, H. and Imai, M.: Control of renal 
function in freshwater and marine teleosts. 
Federation Proc., 41(8):2355-2360, 1982. 
Figure 3. A Schematic Illustration of Freshwater Teleost 
Nephron Function. 
Assays for Gentamicin 
Until the early 1970's, the most commonly used assay 
procedure for gentamicin was the microbiological assay. 
In this assay, the concentration of gentamicin in a sample 
is correlated with the size of a zone of inhibited growth 
13 
on an agar plate containing a known type and number of 
bacteria. The advantage of this method is that it mea-
sures the total antibiotic activity in a given sample. 
The disadvantages of this method include low specificity, 
high variability, and a long assay time. The latter prob-
lem was resolved in the late 1960's when it was shown that 
the antibiotic activity of a sample inhibited long fermen-
tation to cause a measurable pH change in the growth media 
in one to two hours. 46 Gentamicin concentration is cor-
related with the rate of pH change in the zone of inhibi-
tion over a 90 minute period. This rapid microbiological 
assay is still hindered by the problems of low specificity 
and high variability. 
The problem of specificity was largely overcome in 
the early 1970's with the development of the enzymatic 
assays for gentamicin. The first enzymatic assay deve-
3 loped used H-labeled ATP to adenylate the aminoglyco-
side. 47 The adenylation product is counted in a 
scintillation spectrometer and compared with counts from 
known standards. The specificity and reproducability of 
the enzymatic assay was further enhanced when a 14c-
labeled ATP adenylation agent replaced the 3H-labeled ATP 
d . 48 use earlier. 
In the mid-1970's, a radioimmunoassay (RIA) was deve-
125 loped using an I-labeled acylating agent to iodinate 
gentamicin that was in turn mixed with rabbit antibody 
14 
and unlabeled gentamicin from a sample of unknown concen-
tration. 49 125I-labeled and unlabeled gentamicin conju-
gated competitively with antibody. Free gentamicin was 
removed with dextan coated charcoal and the radioactivity 
of aliquots of supernatant was measured and compared to 
standards. This RIA was more specific and less variable 
than the previous enzymatic assays, but still required a 
few hours to set up and run. This final problem was 
finally resolved with the advent of the second antibody 
125 . . . . d . b d ( RIA. The I-gentamicin, secon anti o y RIA system see 
Figure 4) proved to be fast, sensitive, accurate, simple 
so 
and able to produce very consistent assay values. 
<f;-Ge~t] 
<c-&-e~tl 
. 125 b d . . . H-Gent is I-la ele gentamicin, C-Gent is sample genta-
micin, lstAb is the antibody that will bind with genta-
micin and 2nd.Ab is the antibody that will bind with the 
lstAb to form a precipitate. H-Gent and C-Gent will 
reach an equilibrium with the lstAb, that is dependent 
on their respective concentrations. The percentage of 
2ndAb-lstAb bound to H-Gent will be inversely propor-
tional to the amount of C-Gent added from the sample 
of unknown concentration. 
· 125 ' ' d An 'b d RIA R t. Figure 4. I-Gentam1cin Secon ti o y eac ion. 
CHAPTER II 
MATERIALS AND METHODS 
General Information 
The Schering veterinary product Gentocin®a, gentami-
cin sulfate, was used as the gentamicin sulfate source for 
all the studies described in this chapter. Each milli-
liter of Gentocin® contained 50 mg gentamicin base. All 
fish used in these experiments were purchased from a 
' . b . 
single commercial source in February and early March of 
1982. ( 125 ) . ' . d " I -Gentamicin Second Antibo y Buffer System", 
radioimmunoassay kitsc (hereafter referred to as RIA kits) 
were used for all quantitative gentamicin assays mentioned 
in this chapter. 
Assay Validity Study 
Materials and Procedure 
Three stock solutions (A, B and C) of gentamicin sul-
fate were made. Forty-nine ml of deionized water were 
aGentocin® (Control Nos. 9KMF29 P62883 and IKMFlO 
P66395), Schering Corp., Bloomfield, New Jersey. 
bCrawford's Catfish Acres, Inc., Shawnee, Oklahoma. 
cAntibodies Incorporated, Davis, California 95616. 
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added to 1 ml of Gentocin® to yield the 1 mg/ml solution, 
stock solution A. Four ml of deionized water was added to 
1 ml of Gentocin® to yield the 10 mg/ml solution, stock 
solution B. One ml of deionized water was added to 1 ml 
of Gentocin® to yield the 25 mg/ml solution, stock solu-
tion C. These three stock solutions were used to spike 1 
ml aliquots of heparinized catfish plasma to yield O, 1, 
2, 5, 10, 15 and 30.Ag/ml standards (Table I). Additional 
catfish plasma standards were formulated (see Table I) for 
the supplemental assays that were performed to enhance the 
statistical significance of the standard curves generated 
by the initial human serum and catfish plasma standards. 
The catfish plasma was collected by exanguinating a number 
of 8 to 13 cm channel catfish. The O, 1, 2, 4, 8, 16 and 
32µg/ml human serum standards from the RIA kits were 
used as packaged. 
Assay Procedure 
Each standard concentration sample was prepared for 
assay by adding 50 µl of sample to 10 ml of 0.9% saline in 
a 16 x 125 mm polystyrene test tube. Five sets human 
serum and five sets catfish plasma standard concentration 
samples were assayed. 
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TABLE I 
ASSAY VALIDITY STUDY STANDARD FORMULATIONS 
Catfish Plasma Heparinized Cat- Volumes of Stock 
Standard Concen- fish Plasma Solutions Added to 
tration (.M.g/ml) Volume (ml) Catfish Plasma 
0 1.0 0 .A.ll 
1 1. 0 1 ....ul A 
2 1. 0 2 .Ml A 
6 0.5 3 Al A 
5 1. 0 5 ,ul A 
10 1. 0 1 ,,ul B 
15 1. 0 5 µl A + 1 _µl B 
16 0.5 3 ,....ul A + 0.5 Al B 
30 1.0 5 µl A + 1 ,.ul c 
35 1. 0 1 fil B + 1 µl c 
A is a 1 mg/ml gentamicin sulfate solution; B is a 
10 mg/ml gentamicin sulfate solution; C is a 25 mg/ml gen-
tamicin sulfate solution. 
The assay procedure was performed as described in the 
RIA kit's instruction booklet. The procedure is para-
phrased as follows: 
1. Label a duplicate set of 12 x 75 mm polystyrene 
test tubes for each human serum, catfish plasma and 0.9% 
saline standard. 
2. Pipet 50,µ.l of each 1:201 standard dilution into 
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the appropriate tubes. 
3 P . t 500 1 f ( 125 ) . . d . . ipe A o I -Gentam1c1n Secon Antibody 
Buffer into each tube. 
4. Pipet 500µ1 of gentamicin antiserum into each 
tube. Thoroughly vortex each tube immediately after the 
addition of the antiserum. 
5. Incubate all tubes at room temperature for at 
least 30 minutes. 
6. Centrifuge all tubes for at least 10 minutes with 
a minimum force of 2000 x g. 
7. Individually, thoroughly decant and discard the 
supernatant. Press each inverted tube against plastic 
backed absorbent paper to remove any residual supernatant. 
8. Count the precipitate in a gamma counter for 1 
minute or a time sufficient to accumulate a minimum of 
10,000 counts, whichever is greater. 
Assay Calculations 
The average counts (x cpm) for the 0 ,µ-g/ml human and 
catfish standards were calculated and designated B0 for 
125 their respective standard sets. The ( I) bound was cal-
culated as a percentage of B (%B/B ) (see equation 2-1). 
0 0 
%B/B = x cpm for a standard x 100 % 
o B [2-1] 
0 
The %B/B values and corresponding human serum and catfish 
0 
plasma standard gentamicin concentrations were used to 
generate log-regression lines of best fit for each set of 
19 
standards using the equation: y = m(log x) + b. In the 
regression equation, y was the %B/B0 of a given sample, x 
was the concentration of gentamicin corresponding to that 
%B/B , m was the slope of the regression line (see equa-
o 
tion 2-2) and b was the %B/B0 corresponding to the y 
(log x)y -
m = 
[:(log x) 2 -
£(log x)r'.y 
N 
[L(log x) J2 
N 
[2-2] 
intercept of the regression line (see equation 2-3). The 
b = L:y - m[L(log x)] [ 2_ 3 ] 
N 
accuracy of the calculated regression line's fit to the 
data and, subsequently, the reliability of the regression 
line as a predictor of values was expressed as a fraction 
of one, called the correlation coefficient (r) (see 
equation 2-4). An r value of one represented 100% reli-
ability and fit. 
r = m(s of sample gentamicin concentrations) 
s of %B/B 's [2-4] 
0 
Mean y intercept (Y ) and slope (m) was calculated 
XO 
for both of the standard groups. The number of values 
(n), variance (s 2 ) and standard deviation (s = ..,r;;2) of 
both groups were also calculated for the mean values 
reported (see equations 2-5 and 2-6). The averaged slopes 
S- 2 = y 
XO 
CLY ) 2 
'[(Y ) 2 _ XO 
XO n 
n - 1 [2-5] 
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2 (Em) 2 
s-2 
m 
= m n [2-6] 
n - 1 
and y intercepts of the two mean regression lines were 
compared as unpaired observations with unequal variances. 
Confidence statements about the homogeneity of the slopes 
and y intercepts were developed using t• tests (see 
equation 2-7). The t' criterion was distributed as 
t' = 
Mean Value 1 - Mean Value2 
sa [2-7] 
Student's t at n-1 degrees of freedom when n 1 = n 2 • The 
standard deviation of the mean difference (sd) was calcu-
lated as the square root of the sum of the variance of 
the means of the catfish plasma and human serum standard 
sets (see equation 2-8). 
s- = d [2-8] 
For confidence intervals stating there is more than a 
10% chance that the difference in reported values is not 
due to random chance alone, calculated values (i.e. plasma 
concentrations) were compared to support or refute the 
assertion that there was no significant difference 
between values. 
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Gentamicin Intracardiac Bolus 
Pharmacokinetic Study 
Materials and Procedure 
A microliter pipetted was used to measure 1.5 ml of 
Gentocin into a 10 ml volumetric flaske. The 1.5 ml Gen-
tocin was diluted to 10 ml with deionizedf and filteredg 
water. This 7.5 mg/ml stock solution was used as the 
gentamicin source for all intracardiac and intramuscular 
dosages. The 10 ml, ground glass stoppered volumetric 
flask, containing the 7.5 mg/ml gentamicin stock solution, 
was sealed with Parafilmh and held at room temperature 
(20°c to 24°c) when not in use. 
Channel catfish weighing between 0.3 kg and 1.7 kg 
were held in a l.5i x 3' x 4', epoxy sealed, aerated 
holding tank for at least 3 days before use as experi-
mental subjects. '\The holding tank water was filtered 
through a submerged, activated charcoal and gravel car-
tridge filter. A covered, 20 gallon all-glass aquarium 
dOxford Sampler® micropipettes, Oxford Laboratories, 
Foster City, California 94404. 
eKimax, No. 28017-A. 
fBarnstead "ROpure" (mod. D2610), Sybron Corp., 
Boston, Massachusetts. 
gBarnstead "NANOpure" (Mod. D2782), Sybron Corp., 
Boston, Massachusetts. 
h ' I b ' ' Parafilm "M' La oratory Film, American Can Co., 
Dixie/Marathon, Greenwich, Connecticut 06830. 
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was used as the experimental tank. Experimental tank 
water was filtered through a bonded filter pad1 and acti-
vated charcoal gravel circulating filter systemj and was 
aerated. No fish were fed during holding or experimenta-
tion and no fish were held longer than six days before use 
and disposal. Holding and experimental tank temperatures 
were maintained at 22°c ~ 2°c. Tank water pH's were moni-
toredk and maintained at 6.9 ~ 0.1. 
The first catfish, E1c1 , was run as a trial fish and 
was used to establish an appropriate sampling schedule for 
the other nine fish. A 100,µl heparinized intracardiac 
blood sample.was taken through a 25 gauge hypodermic 
needle at time zero. A calculated dose (see equation 
2-9) of the 7.5 mg/ml gentamicin stock solution, rounded 
Calculated 
Dose 
= fish weight x 0.13 fall stock solution [ 2_ 9 ] (in grams) gram of fish 
to the nearest 75 micrograms, was injected through a 25 
gauge needle as an intracardiac bolus immediately there-
after. Disposable tuberculin syringes1 and 25 gauge 
m 
needles were used to obtain 100_µ1 heparinized blood 
iMarineland Aquarium Products Division of Aquaria, 
Inc., Van Nuys, California 91406. Cat. No. 100. 
jThe Aquology Corp., USA, model 10-120. 
kCorning Digital 112 Research pH Meter. 
11.0 cc tuberculin syringe, Becton-Dickinson, 
Rutherford, New Jersey 07070. 
~onoject 200, 25 GA 5/8 A hypodermic needles, Sher-
wood Medical Industries, Inc., Deland, Florida 32720. 
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samples by cardiac puncture at 15 minute intervals for the 
first three hours of the experiment. Subsequent samples 
were taken every 30 minutes for the next two hours and a 
last time twenty-four hours after time zero. Blood sam-
ples were stored and centrifuged in glass microhematocrit 
n . h o tubes blocked on one end wit clay • The catfish plasma 
was stored at s0 c until assayed. E1c1 was hand held for 
bolus administration and sampling, as were all the catfish 
used in this experiment. 
From the kinetic curve generated from catfish E1c1 , 
it was determined that the sampling schedule for the other 
nine fish used in this study would be every 15 minutes for 
the first two hours, every 30 minutes for the next three 
hours, at six and eight hours post injection, and one or 
two times over the next sixteen hours. It was also 
decided that, because of the sampling schedule, three cat-
fish could be sampled during each experimental trial. The 
catfish used in each trial were identified by colored 
tagsp attached to their adipose fins with 3-0 silk 
sutureq. All fish were weighed in a dry plastic tub on a 
nHeparinized Capillary Tubes, Stock No. 30-2501, 
General Scientific, Richmond, Virginia 23228. 
0 Seal-Ease, Ct. No. A-2980, Clay-Adams, Inc., New 
York, New York. 
Pscientific Products labeling tape. 
qBlack braided Type B, Ethicon, Inc., Somerville, 
New Jersey. 
top-loading balancer before being placed in the experi-
mental tank. 
Assay Procedure 
24 
The RIA kit's assay protocol was modified and applied 
to each group of standaids and samples assayed at a given 
time with reagents from a single RIA kit. The modified 
assay protocol was as follows: 
1. Label a duplicate set of 16 x 125 mm polystyrene 
test tubes for each human serum standard from the RIA kit 
and for each catfish plasma sample. 
2. Break hematocrit (Ht) tubes on the plasma side of 
the packed cell fractions and pool the plasma fractions of 
each sample. Discard any hemaglobin stained plasma 
fraction. 
3. Pipet 50_,ul of each human serum or catfish plasma 
standard sample into the appropriately labeled 16 x 125 mm 
polystyrene test tube. 
4. Add 10 ml of 0.9% saline to all 16 x 125 mm poly-
styrene test tubes to yield 1:201 dilutions of standards 
and samples. 
5. Label a duplicate set of 12 x 75 mm polystyrene 
test tubes for each 1:201 dilution of human serum standard 
or catfish plasma. 
rSartorius-Werke Kilomat, Type 2113 gram scale. 
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6. Pipet 50.,.Ml of each of the 1:201 human serum 
standard and catfish plasma sample dilutions into the 
appropriate 12 x 75 mm tube and· its contents. 
. 0 ( 125 ) . . d A . b d 7. Pipet 50 µl of I -Gentamicin Secon nti o y 
Buffer into each 12 x 75 mm tube. 
8. Pipet 500 _µl of gentamicin antiserum into each 
tube. Thoroughly vortex each tube immediately after the 
addition of the antiserum. 
9. Incubate all tubes at room temperature for at 
least 30 minutes. 
10. Centrifuge all tubes for at least 10 minutes with 
a minimum force of 2000 x g. 
11. Thoroughly decant and discard the supernatant. 
Press each inverted tube against plastic backed absorbent 
paper to remove any residual supernatant. 
12. Count the gamma emissions from the precipitate in 
a gamma counter for 1 minute or a time sufficient to accu-
mulate a minimum of 10,000 counts, whichever yields the 
larger gamma count. Recount each tube at least one time 
within six hours of the initial gamma count. 
Assay Calculations 
The %B/B vs. log human serum gentamicin concentra-
o 
tion, linear regression line for each assay group was used 
to estimate the gentamicin concentrations in the catfish 
plasma samples of each assay group (see equation 2-10). 
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log- 1 (%B/B of Y 
0 XS 
- %B/B of Y ) 
0 XO [2-10] 
m 
The catfish plasma gentamicin concentration (Cp) was cal-
culated as the antilog of the sum of the negative value of 
the %B/B0 of the human serum standard regression line y 
intercept (-%B/B of Y ) and the fraction (%B/B of Y ) 
0 XO 0 XS 
in which the x cpm of the catfish plasma sample is the 
numerator and the x cpm of the O_µg/ml (i.e. pre-injec-
tion) catfish plasma sample is the denominator. Equations 
2-2 and 2-3 from the Assay Validity Study were applied to 
determine the slope and y intercept of the linear regres-
sion line for each assay group. A unique regression line 
was calculated for each assay group from RIA kit human 
serum standards assayed with that particular set of cat-
fish plasma samples. 
The plasma gentamicin concentration curve (hereafter 
referred to as the concentration curve) for each catfish 
s 
was plotted on three cycle semi-logarithmic graph paper 
with plasma gentamicin concentration (hereafter referred 
to by the acronym pgc), inµg/ml, plotted on the dependent 
(y) axis and time, in minutes, plotted on the independent 
(x) axis. The inflection point at which the concentration 
curve appeared to change slope in an abrupt fashion was 
determined by visual inspection of the curve of best fit 
sK-E Semi-logarithmic, 3 cycles x 70 divisions. 
Keuffel & Esser Co., USA. 
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plotted through the data points. The slope of the con-
centration curve after this inflection point was con-
sidered to be the slope of the elimination phase of the 
curve. The slope of the concentration curve prior to this 
inflection point was considered to be the sum of the 
slopes of the distribution and elimination phases and was 
referred to as the d+J& portion of the curve (see Figure 
5). The distribution phase was labeled as the alpha phase 
and the elimination phase was labeled as the beta phase. 
plasma 
gentamicin 
concentration 
Cug/ml) 
point 
s8is the region of the curve where the slope is due 
to elimination phase kinetics only. The elimination phase 
is called the beta phase. c<.+;6' is the unfeathered region 
of the curve where the slope is the sum of the slopes of 
distribution and elimination phase kinetics. The distri-
bution phase is called the alpha phase. These two regions 
are separated by a vertical line passing through the 
inflection point of the curve. 
Figure 5. Hypothetical Plasma Gentamicin Concentration 
Kinetic Curve. 
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A least squares regression line was calculated for 
the region of the concentration curve identified as the 
beta phase. From this line of best fit, the y intercept, 
B (Mg/ml), and the negative value of the slope of the beta 
-1 phase,_,O>(min ), could be calculated. iJ was the microcon-
stant representing the rate, in reciprocal minutes, at 
which gentamicin was eliminated from the blood plasma. A 
second least squares regression line was calculated for 
the assayed gentamicin plasma concentration points in the 
o<..+KJ portion of the concentration curve. The y intercept 
of this regression line was the theoretical zero time pgc 
in micrograms per miililiter, c0 • The slope and y inter-p 
cept of the hypothetical regression line describing the 
distribution phase was derived by a process called 
feathering wherein the ¢'phase regression line was sub-
tracted from the d..+y8 regression line. The y intercept 
of the alpha phase regression line, A (µg/ml), was deter-
0 
mined by subtracting B from C (see equation 2-11). The p 
A = c0 - B [2-11] p 
negative value of the slope of the alpha phase regression 
line, c;<(min- 1 ), was derived by subtractin9.J8from the 
negative value of the slope of the least squares regres-
sion line through the assayed pgc points in the o< + ft8 
' ( ' -1) portion of the concentration curve, me min (see equa-
tion 2-12). oc was the constant representing the rate, in 
[2-12] 
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reciprocal minutes, at which gentamicin was distributed 
throughout the central and peripheral compartments. 
The experimental constants, A, B, 0( and t3 1 were used 
to calculate the pharmacokinetic microconstants K21 , Kel 
and K12 (see equations 2-13, 2-14 and 2-15) in reciprocal 
minutes. 
= A(JB) + B (~) 
co 
p 
K = (oe) ~) 
el K21 
[2-13] 
[2-14] 
[2-15] 
The alpha half-life, t~(0<:.)' and beta half-life, 
t~(,r&), were calculated by dividing oc and iJ into the natu-
ral logarithm of 2 (see equations 2-16 and 2-17) and 
tloz (oe) 
reported in minutes. 
= ( ln 2) 
oc 
= ( ln 2) 
~ 
[2-16] 
[2-17] 
The apparent volume of the central compartment, Ve 
(in ml/kg body weight), was calculated by dividing the 
intracardial gentamicin dose, in mg/kg, by the peak plasma 
gentamicin concentrations, in,µg/ml (see equation 2-18). 
V = Dose x 1000 ml/l 
c co 
p 
[2-18] 
The volume of fluid, in ml/kg, required to contain 
the amount of gentamicin in a given catfish, if it had 
been uniformly distributed throughout that fluid at a 
concentration equal to that in the plasma (i.e. c0 ) was p 
called the apparent volume of distribution. The area 
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method of calculating the apparent volume of distribution 
was utilized in these calculations (see equation 2-19). 
vd(area) = 
Dose 1000 ml/l [2-19] (A,.6c + B,ig) x 
The extrapolation method was also used to calculate an 
apparent volume of distribution (see equation 2-27) that 
could later be compared to the Vd(B)'s of the intramuscu-
lar injection study. 
The product of the apparent volume of the central 
compartment, Ve' and the overall elimination rate con-
stant, Kel' was the volume of the blood, in ml/kg, cleared 
of gentamicin per minute, ClB (see equation 2-20). 
ClB = Kel • Ve [2-20] 
Plasma gentamicin concentrations (flg/ml), C~, were 
calculated at t = 240, 360, 480, 720 and 1440 minutes post 
injection (see equation 2-21). The letter e was used as a 
[2-21] 
symbol for the base for hyperbolic logarithms, 2.71828 ••.• 
In an attempt to propose a rational course of multi-
ple dose gentamicin therapy, minimum (2.).{g/ml) and maximum 
( 12 _Ag/ml) therapeutic gentamicin plasma concentratins 
were used to arithmetically predict and evaluate dosage 
strength and frequency. In equation 2-22, the initial 
dose, D. (mg/kg), was the product of the maximum allowable 
l 
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D. = 
l 
cm v 
p(max) · d(area) [2-22] 
1000 ,,ug/mg 
plasma gentamicin concentration, Cm and the p(max)' 
apparent volume of distribution. The subsequent dosage 
frequency in minutes, (see equation 2-23), and maximum 
1 (cm • cm ) 
x __ 0_g __ ~p_(~m_a_x-'-)--~ __ ~p-(~m_i_n~)-
"t = t!-z (KJ) log 2 [2-23] 
effective plasma gentamicin concentration C(]) p(max), were 
used to calculate the maintenance dosage, D (mg/kgJ, 
m ----
amount (see equation 2-24) for continuing intravenous 
cm 
p(max) • v d(area) 
1000 .Mg/mg 
(e.g. intracardiac) therapy. 
[2-24] 
The central and peripheral compartment gentamicin 
concentrations (µg/ml) at the end of the calculated multi-
ple dose time interval, 1:', were arithmetically estimated 
for a given initial intracardiac dose, A • The central 
0 
compartment concentration was ~sed as an indicator of 
plasma concentration (see equation 2-25) and the peri-
-c:x /:' 
• e + 
_.L)r.-
• e IO (.. 
[2-25] 
pheral compartment concentration was used as an indicator 
of the average tissue concentration (see equation 2-26). 
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All pharmacokinetic calculations were performed and 
values reported for each experimental subject. Individual 
0 
B, f8 1 Cp' A,O(, K21' Kel' Kl2' t~(cx:)' t~(.eS')' Ve' Vd(area)' 
t 
Vd(B)' ClB' Cp' Di' 'L, Dm' Ac and~ values were averaged 
and reported with standard deviations as experimental 
estimates of population mean values. Values for t~(oc)' 
t t~(RS')' Ve, Vd(area)' Vd(B)' ClB' cp, Di''T' Dm' Ac and AT 
were also calculated from the mean values for administered 
dose, B,rtJ, c~, A,o<:.., K21 , Kel and K12 • 
Gentamicin Intramuscular Dose 
Pharmacokinetic Study 
Materials and Procedure 
The experimental materials and procedures outlined 
for the Gentamicin Intracardiac Bolus Pharmacokinetic 
Study were utilized in this study with the following modi-
fications. 
A catfish weighing between 1.4 kg and 1.5 kg was used 
as the trial fish labeled E2c 1 . The other eight catfish 
used in this study weighed between 0.3 kg and 0.5 kg. 
The first catfish, E2c1 , was run as a trial fish and 
was used to establish an appropriate sampling schedule for 
the other eight fish. A 100,,L<l heparinized intracardiac 
blood sample was drawn immediately before the calculated 
dose (see equation 2-9) of gentamicin was injected into 
the epaxial musculature in the region bounded cranially 
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by the pectoral fins and caudally by the dorsal fin. The 
100 ,Al heparinized intracardiac blood samples were drawn 
at fifteen minute intervals for the first four hours after 
the intramuscular (IM) injection, at thirty minute inter-
vals for the next three hours, then at 14.5, 27.75, 28 and 
29 hours post IM injection. From the kinetic curve gen-
erated with catfish E2c1 , it was determined that the 
sampling schedule for the other eight catfish used in this 
study would be every sixteen minutes for the first two and 
one-half hours, every half hour for the next five and one-
half hours, and at nine hours post IM injection. From ten 
to 24 hours post IM injection, one or two samples were to 
be taken. Because of the sampling schedule, it was pos-
sible to sample four catfish during each experimental 
trial. 
Assay Procedure 
The assay procedure outlined for the Gentamicin 
Intracardiac Bolus Pharmacokinetic Study was also used for 
this study. 
Assay Calculations 
Catfish plasma gentamicin concentrations were deter-
mined as outlined in the Gentamicin Intracardiac Bolus 
Pharmacokinetic Study. 
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The plasma gentamicin concentration curve (hereafter 
referred to as the concentration curve) for each catfish 
was plotted on three cycle semi-logarithmic graph paper 
with plasma gentamicin concentration, in,.ug/ml, plotted 
on the dependent (y) axis and time, in minutes, plotted on 
the independent (x) axis. The portion of the curve exhi-
biting a constant negative slope was determined by visual 
inspection of the curve of best fit plotted through the 
data points. The slope of the concentration curve in the 
constant slope region was considered to be the slope of 
the elimination phase after distribution equilibrium had 
been reached. 
A least squares regression line was calculated for 
the constant slope region of the concentration curve. 
From this line of best fit, they intercept, B (Ag/ml), 
and the negative value of the slope,_,X8(min- 1 ), could be 
calculated. J8 was the overall elimination constant repre-
senting the rate, in reciprocal minutes, at which gentami-
cin was eliminated from the blood plasma. The beta 
. . * . . half-life, t~(e)' was the quotient of the Naperian loga-
rithm of two divided by JB(see equation 2-17). 
The extrapolation method of calculating apparent 
volume of distribution, Vd(B) (see equation 2-27), was 
applied in this study. 
Dose 
Vd(B) = B [2-27] 
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The product of the apparent volume of distribution, 
IM . .D Vd(B)' and the microconstant.JO, was the volume of blood, 
. * in ml/kg, cleared of gentamicin per minute, ClB (see 
equation 2-28). 
[2-28] 
t* 
Plasma gentamicin concentrations, CP' were calculated 
at t = 240, 360, 480, 720 and 1440 minutes post injection 
(see equation 2-29). The time, t, after intramuscular 
Ct* -'"'t 
- Be 1.J p - [2-29]. 
t *" injection for each of these Gp 's were considered to be 
sufficiently long for distribution equilibrium to have 
been reached. 
Dosage frequency, "t'*, was calculated (see equation 2-
30) for maintenance of plasma gentamicin levels between 12 
* 
lo (cm .!. c® ) 
'r* = tiz (r(J) g p(max) · p(min) . x log 2 [2-30] 
,.ug/ml (c:(max)) and 2 .)(g/ml (c:(min)) during multiple dose 
intramuscular therapy. * The initial or loading dosage, D., 
l 
* and subsequent maintenance dosages, D , were determined on 
m 
the basis of therapeutic range of gentamicin plasma con-
centrations and apparent volume of distribution. The 
initial dose was calculated to produce the maximum desir-
able steady state level of 12 ,µg of gentamicin per ml of 
plasma (see equation 2-31). Calculation of the mainten-
D. * = l 
cm v IM 
p(max) • d(B) 
1000 _Ag/mg [2-31] 
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ance dosage was based on the maximum plasma gentamicin 
level, 12 µg/ml, to be achieved during each dosage inter-
val,~ (see equation 2-32). 
D * = m 
c® IM ( - e -ar) 
p ( max ) • V d ( B ) • 1 
1000 ,ug/mg [2-32] 
All pharmacokinetic calculations were performed and 
values reported for each experimental subject. Individual 
* * t* B,tJ, tfz(.~)' Vd(B)' ClB' CP, Di*,'t"* and Dm* values were 
averaged and reported with standard deviations as experi-
mental estimates of population mean values. Values for 
* * t* 
tfz (K3), V d ( B), ClB, CP , Di*, ?:'* and Dm * were also calcu-
lated from the mean values for administered dose, B and 
An estimate of gentamicin intramuscular bioavailability 
(F) was calculated by dividing the area under the mean 
elimination phase regression line for the intramuscular 
dosage study, (AUC)IM' by the area under the mean elimina-
tion phase regression line for the intracardiac bolus 
study, (AUC)IC (see equation 2-34). The apparent volume 
of distribution value Vd(B) was used as an estimate of the 
area under the mean elimination phase regression line, 
AUC, that was defined as the integrated product of JCJDctdt 
0 p 
t 
where C dt was the product of B and the mean value for p 
ct at t =CJD (see equation 2-33). p 
AUC 
F = 
(AUC)IM 
x 100% (AUC)IC 
[2-33] 
[2-34] 
Gentamicin Tank Dosage 
Pharmacokinetic Study 
Materials and Procedure 
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Gentocin (equivalent to 50 mg/ml gentamicin) was 
used as the gentamicin source for tank dosage. Tank water 
was dosed at 6.6 mg/l (0.5 ml/gal). An aerated, 20 gal-
lon, all-glass aquarium was used as the experimental tank. 
The holding tank was set up and used as previously des-
cribed in the Gentamicin Intracardiac Bolus Pharmacokine-
tic Study. Holding and experimental tank temperatures 
were maintained at 22°c ~ 2°c and tank water pH's were 
monitored. 
A catfish weighing between 0.7 kg and 0.8 kg was 
used as the trial fish labeled E3c 1 • The other nine cat-
fish used in this study weighed between 0. 8 kg and 1. l kg. 
All catfish were weighed and identified, as outlined in 
the intracardiac study, before use as experimental sub-
jects. 
The first catfish, E3c 1 , was run as a trial fish and 
was used to establish an appropriate sampling schedule for 
the other nine fish. A 100,,,.«l heparinized intracardiac 
blood sample was drawn immediately before E3c 1 was intro-
duced into the experimental tank containing a calculated 
dose of 7.)-lg of gentamicin per milliliter of tank water. 
A 25 GA, 7/8 inch hypodermic needle was used to draw each 
100_µ1 heparinized intracardiac blood sample. Blood 
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samples were drawn at fifteen minute intervals for the 
first four hours, at half-hour intervals for the next 4.5 
hours, and at 10.5, 12.5 and 27 hours after introduction 
into the experimental tank. Water samples were taken 
hourly for the first seven hours and at 8.5, 10.5, 12.5 
and 27 hours after E3c1 was introduced into the experi-
mental tank. 
From the data generated from catfish E3c1 , it was 
determined that blood was to be drawn from the remaining 
nine catfish at hourly intervals for the first thirteen 
hours, at seventeen hours and once again 21 to 24 hours 
after introduction into the experimental tank. Water 
samples were to be taken each time blood samples were 
taken. 
Assay Procedure 
The assay procedure outlined for the Gentamicin 
Intracardiac Bolus Pharmacokinetic Study was also used for 
this study. 
Assay Calculations 
Catfish plasma gentamicin concentrations were deter-
mined as outlined in the Gentamicin Intracardiac Bolus 
Pharmacokinetic Study. 
The plasma gentamicin concentration curve (hereafter 
referred to as the concentration curve) for each catfish 
was plotted on three cycle semi-logarithmic graph paper 
39 
with plasma gentamicin concentration, in,Mg/ml, plotted on 
the dependent (y) axis and time, in minutes, plotted on 
the independent (x) axis. The water gentamicin concentra-
tion curve corresponding to each catfish was plotted on 
the same graph as that individual catfish's plasma concen-
tration curve. 
The time of peak plasma gentamicin concentration and 
level of the average steady state plasma gentamicin con-
centration were to be determined. The relationship 
between water gentamicin levels and average steady state 
plasma gentamicin levels were to be elucidated. 
CHAPTER III 
RESULTS 
General Information 
Raw data is listed in Appendix A. Values derived 
from the raw data are tabulated in Appendix B. 
Assay Validity Study 
Regression lines were generated for five different 
human serum and five different catfish plasma standard 
sets. The mean y intercept (%B/B ) for the human serum 
0 
standards was 92.34% (s = 3.57%) and the mean slope was 
-40.52 (s = + 0.99). For the five different catfish 
plasma standard regression lines, the mean y intercept 
was 82.05% (s = ~ 6.34%) and the mean slope was -37.98 
(s = + 3.51). All standard set regression line 
correlation coefficients were in excess of 0.96. 
There was less than a 4% chance that the difference 
in Y 's for the human serum standards and catfish plasma XO 
standards was attributable to anything other than random 
chance alone. There was more than an 80% chance that 
40 
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random sampling error alone, rather than a real difference 
in population means, was responsible for the difference in 
m's between the human serum standards and catfish plasma 
standards. 
The m's of the human serum standards and catfish 
plasma standards have overlapping value ranges at~ 0.6 
standard deviation units. At a hypothetical common %B/B 
0 
of 90%, the difference in calculated gentamicin sample 
concentrations are less than l,.,Ug/ml at binding values 
greater than 55% (i.e. less than 8,,Ug/ml). 
Gentamicin Intracardiac Bolus 
Pharmacokinetic Study 
The mean beta half-life of gentamicin given as an 
intracardiac bolus was 13.8 (s = ~ 4.7) hours and the 
mean alpha half-life of gentamicin was 54.12 (s = ~ 61.96) 
minutes. The apparent volume of the central compartment 
was 61.46 (s = ~ 49.8) ml/kg. The volume of fluid 
required to contain the dose of gentamicin given, if it 
were uniformly distributed at a concentration equal to 
that in the plasma, (Vd( )) was calculated to be 212.04 area 
(s = ~ 96.92) ml/kg. The microconstants K12 , K21 and Kel 
( ) . -1 were calculated to be 0.195 s = ~ 0.196 min , 0.0048 
-1 -1 (s = ~ 0.0025) min and 0.0074 (s = ~ 0.0089) min , 
respectively. Gentamicin was cleared from catfish plasma 
at a rate of 0.1983 (s = ~ 0.1608) ml/min/kg after intra-
cardiac bolus administration. The value of o<. was 0.0307 
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(s = ~ 0.028) . -1 min of f(3 was 0 • 0 0 0 9 ( s = ~ 0 • 0 0 0 3 ) . -1 min 
of A was 54.62 (s = ~ 101.18)~g/ml and of B was 4.85 (s = 
1.96),.Ag/ml. A graphic representation of the plasma decay 
curve described by mean ct values generated from intra-
P 
cardiac bolus injection study data is given in Figure 6. 
The initial intracardiac dose of gentamicin required 
to yield a peak plasma level of 12 )Ag/ml was calculated to 
be 2.43 (s = ~ 1.12) mg/kg. The intracardiac dosage 
interval,'L, required to prevent trough plasma levels in 
excess of 2µg/ml was calculated to be 35.71 (s = ~ 12.16) 
hours. The maintenance intracardiac dose was calculated 
to be 2.06 (s = ~ 0.93) mg/kg when administered at the 
dosage interval,!:. At the end of each dosage interval 
the gentamicin concentration in the central compartment 
(e.g. blood plasma) was predicted to be 0.133 (s = + 
0.308) Ag/ml. The average tissue concentration at the end 
of the dosage interval was expected to be 0.295 (s = + 
0.616) ~g/ml, given the assumption that the calculated 
value for peripheral compartment drug level, AT' accu-
rately predicted tissue levels. 
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This curve is derived from the time ending the o<..+JB phase 
(156 + 36 minutes) and the mean values, in..-'{g/ml, for c0 
(59.37 ~ 102.2), B (4.85 + 1.96) and c~ at t = 240, 360~ 
480, 720 and 1440 mi~utes. Peak values at 240 minutes 
were estimated from raw data values. Standard deviation 
ranges are given with C~ value~: d = 4.02 ~ l.~8; f = 
3.49 + 1.34; h = 3.22 + 1.17; l = 2.49 ~ 0.95; J = 1.33 
+ 0.54. 
Figure 6. Composite Intracardiac Bolus Gentamicin Plasma 
Decay Curve. 
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Gentamicin Intramuscular Dose 
Pharmacokinetic Study 
The mean beta half-life of gentamicin given intramus-
cularly was 9 (s = ~ 1.94) hours. The apparent volume of 
distribution was calculated to be 365.78 (s = + 74.83) 
ml/kg. Gentamicin was cleared from catfish plasma at a 
rate of 0.3484 (s = ~ 0.0777) ml/min/kg after intramuscu-
lar administration. The mean value of/3 was 0.0009 (s + 
) . -1 0.0002 min and the mean value of B was 2.86 (s = + 
0.5l)_p.g/ml. A graphic representation of the plasma decay 
curve described by mean ct values generated from intramus-p 
cular injection study data is given in Figure 7. 
The initial intramuscular dose of gentamicin required 
to yield a peak plasma level of 12µg/ml was calculated to 
be 4.39 (s = ~ 0.90) mg/kg. The intramuscular dosage 
interval, 'T*, required to prevent trough plasma levels in 
excess of 2 µg/ml was calculated to be 31. 83 ( s = + 5. 01) 
hours. The maintenance intramuscular dose was calculated 
to be 3.64 (s = ~ 0.74) mg/kg when administered at the 
dosage interval, 1:*. 
The estimate of the bioavailability of intramuscu-
larly administered gentamicin in the channel catfish was 
59%. 
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This curve is derived from the mean values, in.Mg/ml, 
for B (2.86 .:!:. 0.56) and ci at t = 240, 360, 480, 720 and 
1440 miny.tes. Peak values at t 240 minutes were esti-
mated from raw data values. Standard deviation ranges are 
given with C~ values: 1 = 2.26 + 0.38; p = 2.02 .:!:. 0.34; 
q = 1.79 + 0.30; u = 1.43 .:!:. 0.25; z = 0.72 .:!:. 0.17. 
Figure 7. Composite Intramuscular Dose Gentamicin Plasma 
Decay Curve. 
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Gentamicin Tank Dosage 
Pharmacokinetic Study 
The catfish identified as E3c1 , E3c2 , E3c5 , and E3c8 
did not show significant elevation in plasma gentamicin 
levels. The catfish labeled E3c4 , E3c7 and E3c10 did show 
some elevation in plasma gentamicin levels. At greater 
than 240 minutes, E3c4 had an average plasma gentamicin 
level of 1.0 (s = + 1.4) _,tig/ml. Before 450 minutes, E3c9 
averaged 1.1 (s = + 1.3) ,Mg gentamicin per ml blood 
plasma. When averaged over the entire span of time blood 
levels were monitored though, the mean values for E3c4 
and E3c9 fell below the l,Ag/ml level considered to be the 
lower end of the regression analysis' range of reliable 
correlation of %B/B to sample concentration. The mean 
0 
plasma level for E3c7 was 3.3 (s = + 0.28)Ag/ml and was 
1.5 (s = ~ 0.8),t<g/ml for E3c10 • These plasma levels for 
E3c7 and.E3c10 were avera~ed over the entire sampling time 
for which each catfish was monitored and were above the 1 
Ag/ml regression line minimum reliably predictive value. 
Regression lines developed for tank water gentamicin 
concentrations indicated that catfish E3c1 was exposed to 
a tank dosage range of 8 ,Mg/ml to 6 Ag/ml; E3c2 , E3c3 and 
E3c4 were exposed to a dosage range of 8.4.,ug/ml to 6 
,,l(g/ml; E3c5 , E3c6 and E3c7 were exposed to gentamicin con-
centrations ranging from 7.3_.L(g/ml to 6.9,...u.g/ml, and E3c8 , 
E3c9 and E3c10 were exposed to dosages of gentamicin 
ranging from 6. 5 ,.Mg/ml to 6. O _µg/ml. 
CHAPTER IV 
DISCUSSION 
General Information 
In order to minimize the variability in experimental 
subjects, all catfish used in this study were acquired 
from a single source, during a single season, and were of 
a limited size range. They were maintained without 
feeding for the brief period they were kept before use to 
minimize the chances of fouling the water. It was 
believed that no significant adverse effects resulted from 
the brief period of fasting. The holding tank was coated 
with epoxy paint and sealed with silicone sealant to mini-
mize exposure to exogenous toxic substances. An acti-
vated charcoal filter and extensive aeration were used to 
control biological waste products produced by the fish. 
Since the pH of a catfish's intracellular fluids drops 
0.018 units for every 1°c temperature increase, 42 and 
. . . . . 13 . gentamicin is sensitive to pH levels, the holding tank 
temperature was controlled as best possible. 
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Assay Validity Study 
The high correlation coefficients corresponding to 
the regression lines developed for the human serum and 
catfish plasma standards indicated that these regression 
lines were very reliable for predicting gentamicin concen-
trations from given %B/B0 's. 
The t test used to calculate t' values for unpaired 
observations of unequal variances (equation 2-7) was taken 
d ' 51 from Steel an Torrie. The tabular values of t' were 
distributed as Student's t at n-1 degrees of freedom since 
the same number of standard sets were used in the calcula-
- - 52 tion of catfish plasma and human serum Y 's and m's. 
XO 
The human serum and catfish plasma Yx0 's were considered 
as estimates of a common population mean since there was 
a 96% chance that the difference in the Y 's of the human 
XO 
serum standard regression line and the catfish plasma 
standard regression line was due to sampling error alone. 
While there was a 20% chance that the difference between 
m's Of the catfish human standard regression lines Was due 
to a real difference in population mean slopes, the 
difference in slope values was within 0.6 standard devi-
ation units of the respective slopes. The differences in 
calculated sample gentamicin concentrations due to the 
differences in m values were less than l.,..tlg/ml at these 
plasma concentrations. 
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It was decided to assume that the human serum stan-
dards could be used to reliably predict catfish plasma 
gentamicin levels at concentrations ranging from l..t-<g/ml 
to 8).{g/ml and could be used to predict values outside 
this range with the understanding that the reliability of 
the numbers generated decreased as their values diverged 
from the 1 to 8 ,Ug/ml range. It was believed that formu-
lation error due to small plasma volumes in catfish plasma 
standards could off set the small theoretical advantage of 
using catfish plasma standards instead of the human serum 
standards provided in the RIA kits. The human serum 
standards were used because of convenience, adequate reli-
ability and high standard concentration reliability.· 
Gentamicin Intracardiac Bolus 
Pharmacokinetic Study 
The calculated dose of gentamicin administered to 
the catfish in this study was determined by multiplying 
each fish's body weight, in grams, by the product of 0.2 
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ml extracellular fluid per gram of catfish body weight 
and the arbitrary gentamicin blood level of 5)-.lg per ml 
extracellular fluid, then dividing by the concentration of 
the gentamicin stock solution, 7.5 mg/ml. Doses were cal-
culated volumetrically and rounded to the nearest 10,,bll. 
This 10 Ml was equivalent to about 0.08 mg of gentamicin 
and was responsible for the variation of dosage about the 
1.0 mg/kg mean value. Aspiration of blood into the 25 
50 
gauge needle hub was considered verification that the gen-
tamicin dose was being delivered directly into the circu-
latory system. Work done by Cameron41 suggested that it 
was not likely that renal blood flow or renal output were 
significantly altered by repeated manual restraint and 
cardiac puncture. Post mortem examination of the channel 
catfish used in this study did not reveal any gross ven-
tricular lesion or pericardial blood accumulation from 
repetitive cardiac puncture. 
The %B/B vs. log human serum gentamicin standards 
0 
regression line slope and y intercept values were used to 
calculate catfish plasma sample gentamicin concentrations. 
A unique regression line was developed for each assay set. 
Although sample gentamicin concentrations were comparable 
between assay sets, percent binding values were only 
meaningful when they were compared to other binding values 
within the same set. 
Gentamicin kinetics were thought to be adequately 
described by a two-compartment open mode112126 , even 
though it had been shown that this antibiotic was concen-
trated in the renal cortex13114 and that as much as 10% of 
blood gentamicin may be found associated with red blood 
cells15116 • Because of these compartments of selective 
drug concentration, it might have been more theoretically 
accurate to utilize a more complicated multicompartment 
open model, but the rapidity with which the red blood 
cell compartment was thought to equilibrate with blood 
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plasma and the very slow rate of accumulation of drug in 
renal tissue prevented either compartmental equilibration 
rate from significantly affecting the kinetics described 
by a simple two compartment open model over the calculated 
dosage interval of 33 hours. 
The mean value for K12 (0.0195 min- 1 ) was nearly five 
. -1) times the mean value for K21 (0.0048 min • This indi-
cated that gentamicin moved from the central compartment 
to the peripheral compartment a great deal more rapidly 
than from the peripheral to the central compartment. The 
mean values for Ac (0.133 Ag/ml) and AT (0.295pg/ml) 
supported this assertion. 
The Vd( ) value included both distribution and area 
elimination phase kinetics in the calculation of the 
apparent volume of distribution. Vd(B) was also calcu-
lated, but was of value primarily as an apparent volume of 
distribution value that could later be compared to that 
calculated for the intramuscular dosage study. The larger 
the ratio of OC: fJ , the smaller the area of the 0( +JS 
region of a kinetic curve when compared to the ;tJ region of 
that same curve. The total area under a kinetic curve was 
inversely proportional to the corresponding apparent 
volume of distribution (see equations 2-19 and 2-27). The 
Vd(B) value was expected to overestimate the true apparent 
volume of distribution of a drug whose kinetics could best 
be described by a two compartment open model since the one 
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compartment model extrapolation method did not take dis-
tributive phase kinetics into consideration. 
The difference in the calculated mean estimates of 
Vd(area) (156.56 ml/kg) and Vd(B) (208.25 ml/kg) was com-
12 parable to that seen in the dog. These calculated esti-
mates of mean apparent volumes of distribution compared to 
the fluid compartment values of 680 ml/kg for total body 
water, 190 ml/kg for extracellular fluid and 490 ml/kg for 
41 
intracellular fluid in channel catfish. Since the cal-
culated estimate of Vd( ) value did not exceed the 
area 
expected volume of extracellular fluid in the channel cat-
fish, it was assumed that gentamicin was not significantly 
partitioned into a subdivision of the central compartment 
such as red blood cells endothelium or perivascular fluid. 
The t 1 values calculated from mean 0( and rJ3 values 
"2 
showed a beta half-life (770.2 min) more than 34 times the 
alpha half-life (22.6 min). This was a greater difference 
than normally seen in mammals. 12113123124 Following 
intracardiac bolus administration, the long alpha half-
time and the delayed (35 ~ 15 min) peak plasma concentra-
tion could have been due to the disequilibrium parti-
tioning of gentamicin into red blood cells accompanied by 
a protracted bolus dispersal period. As plasma gentamicin 
from the bolus dispersed, aminoglycoside associated with 
red blood cells would move back into the plasma. This 
would cause an apparent rise in the blood gentamicin con-
centration and prolong the time required for complete 
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distribution of drug between the central and peripheral 
compartments. The high concentration of antibiotic in an 
injected bolus could have also caused movement of drug to 
other areas of the central compartment such as endothelial 
cells, perivascular fluid or blood proteins. 
The mean value for Kel was about 25Yo of the amount 
12 
reported for dogs. The low ClB accompanying this Kel 
value indicated that a smaller fraction of total body gen-
tamicin per unit time was eliminated by catfish than by 
homothermic animals. This resulted in the extension of 
the beta half-life beyond that seen in mammals. The c1-
B 
was calculated as the product of the mathematically inde-
pendent parameters Kel and Ve. This method of calculation 
was considered superior to the alternative product of the 
arithmetically related parameters iJ and V The d (area)· 
preferential partitioning of gentamicin into the peri-
pheral compartment, as reflected by the small value of 
K21 relative to K12 , also increased the beta half-time of 
gentamicin. 
The dosage interval for channel catfish at 22 + 2°c 
calculated from a t!z (K]) based on the mean ;8 value and the 
maximal safe peak and trough plasma values was 33 hours. 
This compared with a value of 72 hours reported for gopher 
snakes at 24°c25 and a range of four to six hours for 
man16 • The calculated dosage of gentamicin used in ·this 
study was expected to produce blood levels around the 5 
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_Ag/ml level. The D., Land D values were calculated to 
i m 
allow the maximum peak and trough gentamicin concentra-
tions considered allowable without significant risk of 
aminoglycoside toxicity. The peak plasma concentration 
of 12 pg/ml was above the minimum inhibitory concentration 
reported to be effective against many gram negative and 
. . b .. 8,9 
some gram positive acteria. The initial dosage 
required to achieve a peak plasma concentration of 12 
,,ug/ml, was 2.4 mg/kg. Maintenance dosages required to 
attain peak plasma concentrations of 12,....Ug/ml were 
slightly smaller (2.1 mg/kg). This reduction of the dos-
age required for maintenance of desired plasma drug con-
centration was attributed to saturation of the peripheral 
compartment by the initial dose. 
The risk and technical difficulty involved in cardiac 
puncture in channel catfish made intracardiac bolus injec-
tion an impractical route of parenteral administration for 
use outside the laboratory setting. The practical worth 
of this study was the establishment of basic pharmaco-
kinetic parameters from which information of clinical 
value, such as dosage schedule, bioavailability, clearance 
rate and drug distribution, could be determined. 
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Gentamicin Intramuscular Dose 
Pharmacokinetic Study 
The same considerations concerning dosage calculation 
and determination of plasma sample gentamicin concentra-
tion previously mentioned in the intracardiac bolus study 
discussion apply to the intramuscular dose study. 
,/.)( ' -1) The mean value forx.; 0.0009 + 0.0002 min was the 
same as reported for the ;8 of the intracardiac bolus study 
(0.0009 + 0.0003 min- 1 ). This indicated that the true jJ 
for gentamicin in channel catfish at 22 + 2°c was probably 
' -1 ' very near the 0.0009 min value. Using the value 0.0009 
min-l in the equation for beta half-life (see equation 
2-17), a mean value of t~(,d) = 770.16 minutes was derived. 
Recalculating 'L(see equation 2-30), a new value of 33.18 
hours was indicated. IM Vd(B) was recalculated to be 3S3.1S 
ml/kg by dividing the mean administered dose (1.01 mg/kg) 
by the mean experimental value of B (2.86,A'g/ml). 
Vd(B) was an extrapolated estimator of Vd(area) that 
did not consider the distributive phase (i.e. oC = oo) of 
d d ' ' ' S4 ' ' rug isposition. Because of this, Vd(B) consistently 
overestimated the apparent volume of distribution for 
drugs like gentamicin that were best described by a two-
compartment open model. The assumption was made that the 
ratio of Vd(area):Vd(B) from the intracardiac bolus study 
could be used to estimate a Vd( ) for the intramuscular area 
dosage study. By this method of approximation, the value 
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IM for Vd(B) of 353.15 ml/kg would correspond with a calcu-
lated Vd(area) of 265.64 ml/kg. The ClB corresponding to 
this calculated Vd( )' was 0.2391 ml/min/kg. This area 
value was within 25% of one standard deviation of the 
experimental mean ClB value for the intracardiac study. 
Similar clearance rates would be expected for a drug with 
equal intracardiac and intramuscular beta half times. 
The mean intramuscular dosage study experimental 
values for B and~were used to calculate Di* (4.24 mg/kg) 
and Dm* (3.54 mg/kg). These values deviated less than a 
single standard deviation unit from the mean experimental 
values of 4.39 mg/kg and 3.46 mg/kg, respectively. 
Bioavailability of a drug was a function of both the 
rate of drug absorption and the fraction of the admini-
stered dose that reached the systemic circulation intact. 
It was determined by administering equal doses of a drug 
intramuscularly and intravenously at different times in 
h . 12 t e same animal. This was not done in these experi-
ments. As an estimate of the extent of absorption (F), 
the areas under the composite mean value curves (AUC) from 
the intracardiac and intramuscular studies were compared. 
The apparent volume of distribution value, Vd(B)' 
was used as an estimate of the mean AUC (see equation 
2-33). The fraction of drug that reached the systemic 
circulation after intramuscular administration was calcu-
lated to be 0.59 (59%). This value for bioavailability in 
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channel catfish was only 60% of that reported for mammals 
(>90%). 12 Because of the large variances associated with 
the Vd(B)'s used to calculate F, it was perhaps most 
appropriate to report that the bioavailability of gentami-
cin in channel catfish was near 60%. 
Gentamicin was easily administered as an intramuscu-
lar drug. This study revealed adequate absorption and a 
long plasma half-life. The dosage frequency of 33 hours 
and the small amount of antibiotic required for dosage 
rendered gentamicin a drug of practical use in a clinical 
setting for experimental fish, aquarium fish or aquatic 
breeding stock. 
Gentamicin Tank Dosage 
Pharmacokinetic Study 
Two of the ten catfish involved in this study, E3c7 
and E3c10 , developed significant blood plasma levels with 
exposure to water gentamicin levels between 7.3 and 6.0 
µg/ml. It was not discovered what unique feature common 
to these two fish could have resulted in significant 
absorption of gentamicin from the tank water. It had been 
long assumed that fresh water teleosts did not drink a 
great deal, in an attempt to prevent the relatively hypo-
tonic environmental water from diluting the relatively 
hypertonic internal body fluids. An interesting explana-
tion for the variability in absorption from tank water 
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could have been that only two of the ten fish used in this 
study actually drank the tank water in significant quanti-
ties during the course of an experimental trial. 
Because of the undependable and low-grade absorption 
from tank water and the high potential cost of water 
dosage, gentamicin was not found to be an acceptable anti-
biotic for tank water treatment of systemic bacterial 
infection. These conclusions are in keeping with those of 
. . d k 6 Gilmartin an cowor ers. 
CHAPTER V 
SUMMARY AND CONCLUSIONS 
The purpose of this study was to establish values for 
the common pharmacokinetic parameters applicable to a 
two-compartment open model as they apply to intracardiac, 
intramuscular and oral routes of gentamicin administra-
tion. It was hoped that these values could be used to 
propose a rational course of therapy. The beta half-life 
of gentamicin in channel catfish was estimated to be 770 
minutes. The loading dosage for intracardiac administra-
tion was 2.5 mg/kg and was estimated to be 4.2 mg/kg for 
intramuscular administration. At dosage intervals of 33 
hours, a maintenance intramuscular dosage of 3.5 mg/kg 
could be used to achieve peak serum levels of 12,...ug/ml and 
prevent trough serum levels in excess of 2,Ag/ml. 
Further investigation into the distribution of genta-
micin in the various body tissues would be a valuable 
addition to this body of information and prove helpful in 
better directing use of this aminoglycoside antibiotic in 
the treatment of susceptible gram negative infections. 
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Assay Validity Study 
TABLE II 
HUMAN SERUM STANDARD %B/B 'S 0 0 
%B/B 's for Sample Gentamicin 0 0 
Concentration (,,ug/ml) Standard Lot 
0 1 2 4 8 16 32 
1 100 95.8 86.2 83.9 54.8 45.5 38.0 
2 100 88.4 82.5 64.3 53.1 44.4 30.8 
3 100 89.9 79.5 65.6 49.8 41. 3 29.0 
4 100 88.6 78.6 68.3 52.1 40.4 27.4 
5 100 91.1 79.9 67.6 54.3 42.8 32.4 
%B/B 's 0 0 
for 
Standard 0 
Lot 
1 100 
2 100 
3 100 
4 100 
5 100 
TABLE III 
CATFISH PLASMA STANDARD %B/B 'S 
0 
Sample Gentamicin Concentration 
1 2 5 6 10 15 16 
82.4 71.4 56.2 - 44.1 39.1 -
81. 9 79.3 46.1 
-
40.7 37.4 
-
89.2 85.7 - 58.0 45.2 - 39.5 
74.0 63.4 
-
47.1 41.4 
-
31. 0 
84.1 61.2 
-
51. 3 42.7 
-
33.l 
no value tabulated 
69 
(Mg/ml) 
30 35 
28.1 
-
28.5 -
- 28.6 
-
23.7 
- 22.5 
Gentamicin Intracardiac Bolus 
Pharmacokinetic Study 
TABLE IV 
INTRACARDIAC BOLUS STUDY RAW DATA 
Time Plasma Gentamicin Concentrations, 
Post in.,.u.g/ml, for catfish 
Injection 
El Cl ElC2 ElC3 E1C4 E1C5 E1C6 E1C7 E1C8 E1C9 ElClO (min) 
15 
-
10.6 10.7 61.5 11. 2 5.0 4.1 6.7 5.1 24.1 
31 23.6 
30 - 7.5 8.5 35.2 90.6 5.9 7.0 45.4 8.5 12.8 
45 - 16.6 8.0 27.4 50.1 5.7 14.2 15.1 7.5 9.8 
46 10.7 
60 - 10.5 12.3 19.4 13.8 3.5 4.9 8.7 5.8 8.6 
63 8.1 
75 - 10.3 13.1 12.5 - 2.9 4.0 8.8 9.2 5.2 ..__J 
0 
TABLE IV 
(Continued) 
Time Plasma Gentamicin Concentrations, 
Post in .M.gLrnl , for catfish 
Injection 
El Cl ElC2 ElC3 ElC4 ElC5 ElC6 ElC7 ElC8 ElC9 ElClO (min) 
78 7.3 
90 - 8.2 9.8 12.4 9.6 1. 7 3.6 3.4 6.7 8.3 
105 - 6.2 8.2 5.7 2.6 1. 7 3.0 6.2 4.6 6.5 
108 7.7 
120 - 5.4 12.9 5.9 4.3 1. 8 3.9 3.5 5.2 6.8 
124 8.7 
140 6.2 
150 - 4.5 8.6 6.5 - 1. 5 3.2 4 .1 5.6 6.8 
170 6.1 
180 - 5.5 5.5 4.7 4.5 1.4 3.4 4.5 3.9 3.9 
185 7.9 
210 - 6.0 6.6 2.8 2.0 1.4 2.6 2.5 3.0 5.2 -._.] 
I-' 
TABLE IV 
(Continued) 
Time Plasma Gentamicin Concentrations, 
Post inµg/ml! for catfish 
Injection 
El Cl E1C2 ElC3 E1C4 ElC5 ElC6 ElC7 E1C8 ElC9 ElClO (min) 
240 - 4.9 6.1 4.0 1. 2 1 .• 6 2.6 4. 1 3.4 3.9 
247 5.2 
270 
- 3.8 6.0 2.9 5.5 1. 3 2.8 2.7 2.4 6 .• 4 
277 5.2 
300 - 2.4 4.9 3.2 1. 8 1. 3 2.5 2.2 3.1 4.9 
330 - 3.3 4.5 2.5 4.6 0.8 2.3 2.7 3.4 5.1 
360 
-
3.1 5.2 1. 5 
-
1. 2 2.5 1. 8 3.2 6.0 
480 - 3.8 - 2.6 2.0 1. 0 3.1 
540 
- - - - - - -
1.9 3.2 4.2 
720 - 2.9 2.8 3.0 
1005 - - - .- 1.6 - 2.1 
1320 
- - - - - - - - - -
-J 
N 
Time 
Post 
Injection 
El Cl E1C2 ElC3 (min) 
1380 
-
1. 3 1. 7 
1440 1.9 
- -
mg/kg 1. 3 1. 0 1.0 Dose* 
- = no value tabulated 
* Dose of Gentamicin 
TABLE IV 
(Continued) 
Plasma Gentamicin Concentrations, 
in Ag/ml, for catfish 
E1C4 ElC5 ElC6 E1C7 ElC8 E1C9 
1. 5 
- - - - -
- - - - - -
1. 0 0.9 1. 0 1. 0 1.0 1. 0 
ElClO 
-
-
0.9 
-..J 
w 
74 
Gentamicin Intramuscular Bolus 
Pharmacokinetic Study 
TABLE V 
INTRAMUSCULAR DOSAGE STUDY RAW DATA 
·Time Plasma Gentamicin Concentrations, 
Post in ..tlo/ml, for catfish 
Injec-
ti on E2Cl E2C2 E2C3 E2C4 E2C5 E2C6 E2C7 E2C8 E2C9 (min) 
15 4.6 
16 0.6 3.2 1. 2 4.2 1. 7 2.2 4.0 1. 0 
30 2.6 
32 3.8 3.0 4.6 3.8 3.8 0.9 3.5 2.7 
48 2.2 1. 9 4.8 4.4 3.6 1. 5 3.1 3.6 
50 5.0 
60 1.3 
64 3.3 3.8 3.8 3.3 2.8 1. 8 3.5 3.1 
75 2.9 
80 3.7 2.8 2.8 3.7 3.4 1. 9 3.2 
90 1. 7 
96 2.8 2.6 4.1 1. 7 3.0 2.8 
105 3.0 
112 3.4 3.1 3.4 2.8 
120 1. 8 5.9 2.1 2.6 2.9 
135 2.0 
150 1.6 2.8 1. 7 2.7 
75 
TABLE V 
(Continued) 
Time Plasma Gentamicin Concentrations, 
Post in Ag/ml, for catfish 
Injec-
ti on E2Cl E2C2 E2C3 E2C4 E2C5 E2C6 E2C7 E2C8 E2C9 (min) 
165 1.4 
180 2.1 2.8 2.5 3.6 2.7 1. 7 2.3 
195 2.5 
208 2.4 2.2 2.3 3.6 
210 1. 8 3.0 2.4 3.0 
225 2.1 
240 2.2 1.6 2.0 2.2 2.5 2.8 1.4 1. 7 2.0 
268 2.4 3.6 
270 2.8 2.6 2.6 1.6 
300 1. 8 2.4 2.7 2.3 2.3 1. 8 1. 5 
328 1. 5 1. 6 2.3 2.2 
330 1. 8 2.1 1. 8 2.1 
335 3.0 
360 2.4 1.6 2.0 2.6 2.1 1. 8 1. 7 1. 6 1. 6 
390 1. 5 2.0 1. 0 3.5 1.4 
392 1. 9 1. 3 2.6 2.0 
415 1.4 
420 1. 5 1.4 1.5 1. 5 
424 1. 7 1.4 1. 8 1. 6 
450 1.6 2.2 1. 9 
76 
TABLE V 
(Continued) 
Time Plasma Gentamicin Concentrations, 
Post in A.q/ml, for catfish 
Injec-
E2Cl E2C2 E2C3 E2C4 E2C5 E2C6 E2C7 E2C8 E2C9 ti on 
(min) 
480 
-
1.6 1. 9 1.8 
-
1.9 1. 2 2.2 1. 5 
540 - 1.4 1. 8 1. 9 - 2.5 1. 2 1. 5 1.5 
660 - 1.2 2.0 1.8 2.6 - - - -
855 1. 0 
- - - - - - - -
1080 
- - - - -
1. 2 0.6 0.9 0.9 
1380 
-
0.7 1. 0 1. 0 1. 2 - - - -
1665 0.9 
- - - - - - - -
Genta-
micin 1. 8 1. 0 1.0 1.0 0.9 1.1 1. 0 1. 0 1.1 
Dose 
(mg/kg) 
no value tabulated 
Gentamicin Tank Dosage 
Pharmacokinetic Study 
TABLE VI 
TANK DOSAGE STUDY PLASMA GENTAMICIN CONCENTRATION RAW DATA 
Time 
11 
Plasma Gentamicin Concentrations, 
Post in Mg/ml, for catfish 
Injection 
(min) w:cl E3C2 E3C3 E3C4 E3C5 E3C6 E3C7 E3C8 E3C9 E3Cl0 
15 
30 * 
45 * 
60 * 
75 * 
90 * 
105 * * * * * * 1.1 
120 * - - - - - - 1. 2 1.0 * -....] 
-....] 
TABLE VI 
(Continued) 
Time Plasma Gentamicin Concentrations, 
Post in Ag/ml, for catfish 
Injection 
E3Cl E3C2 E3C3 E3C4 E3C5 E3C6 E3C7 E3C8 E3C9 E3C10 (min) 
135 I I * 
150 I I * 
165 * 
180 * * * * * * 1.4 * * 1.4 
195 I I * 
210 I I * 
225 * 
240 * * * * * * 2.2 * 1. 6 1. 2 
270 * 
300 * * * * * - 1. 3 - 1.3 1. 2 
330 * 
360 - * * * * * 1.1 - * 3.1 -..J co 
TABLE VI 
(Continued) 
Time Plasma Gentamicin Concentrations, 
Post in A /ml, for catfish 
Injection 
E3Cl E3C2 E3C3 E3C4 E3C5 E3C6 E3C7 E3C8 E3C9 E3Cl0 (min) 
390 * 
420 * * 1. 2 * * * 1.1 - 4.0 1.6 
450 4.5 
480 4.2 * * 1.4 * * 1.4 - 1.1 1. 6 
510 3.5 
546 - * 4.1 * * * 1. 3 - * 1.6 
600 
- * * 1. 0 2.8 * 1. 5 - * 1. 5 
630 2.4 
660 - * * 1.3 * * 1. 3 - * 
720 - * - * * * 1. 2 - * 
750 * 
780 * * 1.4 - * -..J - - - - l.O 
Time 
Post 
Injection 
E3Cl E3C2 E3C3 (min) 
810 
- * -
1020 - * -
1380 - * -
1470 - - -
1820 * - -
* = value < 1. 0 ,ag/ml 
no value tabulated 
TABLE VI 
(Continued) 
Plasma Gentamicin Concentrations, 
in .t<g/ml, for catfish 
E3C4 E3CS E3C6 E3C7 E3C8 E3C9 
1.0 - - - - -
* * - 1. 3 - -
4.3 
-
- - - -
- 1. 3 - 1.1 - -
- - - - - -
E3Cl0 
-
-
-
-
-
CD 
0 
81 
TABLE VII 
TANK DOSAGE STUDY GENTAMICIN WATER CONCENTRATION RAW DATA 
Time Post Catfish Group Exposed; Values inAa/ml 
Injection 
E3Cl E3c2,c3;c4 E3c5,c6,c7 E3c8 ,c9 ,c10 (min) 
0 9.3 7.8 6.6 
40 11.4 
60 6.2 7.8 
85 6.5 
105 7.1 
120 8.8 6.2 
160 7.0 
180 9.7 8.9 6.1 
220 6.0 
240 . 7. 9 6.1 7.0 
280 6.5 
300 7.2 6.2 
340 15.5 
360 7.2 6.8 6.8 
400 7.7 
420 8.7 6.6 
460 7.2 
480 7.0 6.8 
510 5.7 
540 6.8 
550 7.2 
580 7.3 
82 
TABLE VII 
(Continued) 
Time Post Catfish Group Exposed; Values in ,.t.lq/ml 
Injection E3Cl E3c2,c3,c4 E3c5,c6,c7 E3C8,C9,Cl0 (min) 
600 - - 6.4 6.1 
630 8.2 - - -
640 - 6.8 - -
660 - - 6.7 5.4 
700 - 7.1 - -
720 - - 6.8 6.3 
750 5.6 - - -
780 - - 6.1 6.8 
790 - 9.4 - -
1000 - 5.4 - -
1020 - - 10.7 -
1360 - 6.4 - -
1470 - - 6.4 -
1620 6.8 - - -
= no value tabulated 
APPENDIX B 
DERIVED DATA 
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Assay Validity Study 
TABLE VIII 
SAMPLE REGRESSION COEFFICIENTS 
y 
-m r 
XO 
Human Serum Standard Lot #1 98.67 40.93 0.972 
Human Serum Standard Lot #2 90.12 39.25 0.994 
Human Serum Standard Lot #3 90.25 41. 28 0.997 
Human Serum Standard Lot #4 90.43 41.46 0.998 
Human Serum Standard Lot #5 91. 21 39.68 0.999 
Catfish Plasma Stan. Lot #1 82.24 37.00 1.000 
Catfish Plasma Stan. Lot #2 82.90 39.44 0.965 
Catfish Plasma Stan. Lot #3 92.32 42.82 0.989 
Catfish Plasma Stan. Lot #4 73.50 33.23 0.997 
Catfish Plasma Stan. Lot #5 79.27 37.43 0.984 
Human Serum 
Standards 
Catfish 
Plasma 
85 
TABLE IX 
MEAN REGRESSION COEFFICIENTS 
2 
n df - 2 n df y Sy Sy -m s s XO m m 
92.34 3.574 12.78 5 4 40. 52 0.993 0.99 5 4 
82.05 6.838 46.77 5 4 37.98 3~514 12.35 5 4 
TABLE X 
DATA PAIRS DERIVED FROM MEAN REGRESSION LINES 
x y x y 
(µg/ml) (%B/B0 ) (..ug/ml) . (%B/B 0 ) 
Human Catfish 
Serum 0 Plasma o. 
Standards Standards 
1 92.34 1 82.05 
2 80.14 2 70.62 
4 67.94 4 59.18 
8 55.75 8 47.75 
16 43.55 16 36.32 
32 31.35 32 24.88 
%B/B0 = -40.52(log x) + 92.34 %B/B = -37.98(logx) + 82.05 0 
TABLE XI 
CALCULATED GENTAMICIN CONCENTRATIONS AND DIFFERENCES 
BETWEEN LINE HS* AND LINE CP* VALUES 
86 
Line HS Calculated Line CP Calculated Difference 
%B/B Gentamicin Concen- Gentamicin Concen-
0 tration (,.Lig/ml) tration (..tlg/ml) 
90 0 0 
80 1. 06 1. 83 
70 3.12 3.36 
60 s.so 6.16 
SS 7.31 8.35 
so 9.71 11. 30 
40 17.14 20.72 
*HS = Human Serum Standard Regression Line: 
%B/B = -40.S2(logx) + 90 
0 
*CP = Catfish Plasma Standard Regression Line: 
%B/B = -37. 98 (log x) + 90 
0 
(.iig/ml) 
0 
0.77 
0.24 
0.66 
1.04 
1. 59 
3.58 
TABLE XII 
PHARMACOKINETIC PARAMETERS FROM THE INTRACARDIAC BOLUS STUDY 
Catfish I c~ A oc B IJ K12 K21 K 1 Time I.D. (µg/ml) -1 (_ug/ml) (min -1 -1 ( ' -1) ( ~ -1) Ending (µg/ml) (min ) (min ) min min o(.+ yJ 
Phase 
(min) 
El Cl 339.41 331. 47 0.0995 7.93 0.0010 0.0668 0.0033 0.0304 100 
ElC2 15.44 10.01 0.0170 5.42 0.0010 0.0088 0.0067 0.0026 180 
ElC3 9.56 2.07 0.0036 7.49 0.0011 0.0015 0.0026 0.0016 210 
E1C4 98.94 94.89 0.0319 4.05 0.0008 0.0187 0.0020 0.0120 150 
E1C5 43.51 40.21 0.0160 3.30 0.0007 0.0087 0.0019 0.0062 180 
ElC6 14.69 12.77 0.0440 1. 92 0.0015 0.0290 0.0070 0.0094 180 
E1C7 7.59 4.35 0.0175 3.24 0.0005 0.0092 0.0078 0.0011 120 
E1C8 22.54 18.82 0.0304 3.72 0.0011 0.0200 0.0059 0.0055 180 
ElC9 7.10 2.93 0.0048 4.17 0.0007 0.0013 0.0031 0.0011 150 
ElClO 34.93 28.66 0.0424 6.27 0.0007 0.0312 0.0082 0.0038 110 
Mean I 59.37 54.62 0.0307 4.85 0.0009 0.0195 0.0048 0.0074 156 Value 
Standard I 102.20 101.18 0.0280 1. 96 0.0003 0.0196 0.0025 0.0089 36 CD Deviation ..._] 
88 
TABLE XIII 
CALCULATED VALUES FROM THE INTRACARDIAC BOLUS STUDY 
Catfish t~ (oC) t~ (J(j) v ClB v Vd(B) I.D. c d(area) (min) (min) (ml/kg) (ml/min/kg) (ml/kg ) (ml/kg) 
El Cl 6.97 684.03 3.83 0.1164 114.83 163.84 
ElC2 40.66 669.51 64.78 0.1716 165.75 184.33 
ElC3 191. 89 611. 07 104.62 0.1657 146.15 133.48 
ElC4 21. 70 905.59 10.11 0.1210 158.19 247.05 
ElC5 43.29 958.02 20.68 0.1273 176.01 273.04 
ElC6 15.77 458.63 68.08 0.6412 424.36 521. 52 
ElC7 39.58 1566.15 131.68 0.1405 297.35 308.11 
ElC8 22.83 650.68 44.35 0.2430 228.15 268.63 
ElC9 143.08 946.43 140.76 0.1586 216.59 239.58 
ElClO 16.32 938.80 25.76 0.0980 132.92 143.48 
Mean 54.21 838.89 61.46 0.1983 212.04 248.31 Value 
Standard 61. 96 282.30 49.80 . 0.1608 96.92 112.90 Deviatior 
Value 
Cal cul a-
ted from 22.58 770.16 17.01 0.1259 156.56 208.25 
Table 
XIII 
Mean 
Values 
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TABLE XIV 
CALCULATED DOSAGE AND COMPARTMENT CONCENTRATION 
VALUES FROM THE INTRACARDIAC 
BOLUS STUDY 
Catfish D. D l A AT l m c I.D. (mg/kg) (mg/kg) (hr) (,Mg/ml) (.Mg/ml) 
El Cl 1. 38 1.15 29.47 0.005 0.147 
E1C2 1.99 1.66 28.84 0.058 0.091 
ElC3 1. 75 1.46 26.33 1.006 2.046 
E1C4 1.90 1.58 39.02 0.007 0.100 
E1C5 2.11 1. 76 41.27 0.011 0.085 
ElC6 5.09 4.24 19.76 0.022 0.114 
E1C7 3.57 2.97 63.16 0.071 0.090 
E1C8 2.74 2.28 28.03 0.028 0.114 
E1C9 2.60 2.16 40.77 0.098 0.053 
ElClO 1. 6.0 1.33 40.45 0.027 0.112 
Mean 2.43 2.06 35.71 0.133 0.295 Value 
Standard 1.12 0.93 12.16 0.308 0.616 Deviation 
Value 
Calcula-
ted from 
Tables 1. 88 1.56 33.18 0.041 0.205 
XII & XIV 
Mean (2.5ot) (2.08t) (o.054t) (o.273t) 
Values 
t Calculated using Vd(B) rather than v d(area) 
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TABLE XV 
CALCULATED PLASMA GENTAMICIN CONCENTRATIONS AT GIVEN 
TIME INTERVALS AFTER INTRACARDIAC 
BOLUS ADMINISTRATION 
Catfish Dose c240min c360min c480min c720minc1440min I.D. p p p p p 
(mg/kg) (µg/ml) (_µg/ml) (.)'g/ml) (,..ug/ml) (Mg/ml) 
El Cl 1. 3 6.22 5.51 4.88 3.82 1. 84 
E1C2 1. 0 4.40 3.76 3.30 2.57 1. 22 
E1C3 1. 0 5.71 4.98 4.35 3.31 1.46 
E1C4 1. 0 3.41 3.07 2.80 2.33 1. 34 
E1C5 0.9 3.63 2.67 3.45 1. 96 1.16 
E1C6 1. 0 1. 33 1.11 0.93 0.65 0.22 
E1C7 1.0 2.96 2.74 2.59 2.31 1.64 
E1C8 1.0 2.90 2.54 2.23 1. 73 0.80 
E1C9 1. 0 4.42 3.72 3.22 2.55 1.46 
ElClO 0.9 5.26 4.81 4.40 3.69 2.17 
Mean 1. 01 4.02 3.49 3.22 2.49 1. 33 Value 
Standard 0.11 1.48 1. 34 1.17 0.95 0.54 Deviation 
Value Calculated 
from Table XII 3.94 3.51 3.15 2.53 1. 33 
Mean Values 
Catfish 
I.D. 
E2Cl 
E2C2 
E2C3 
E2C4 
E2C5 
E2C6 
E2C7 
E2C8 
E2C9 
Mean 
Value 
Standard 
Deviation 
TABLE XVI 
PHARMACOKINETIC PARAMETERS AND CALCULATED VALUES FROM THE 
INTRAMUSCULAR DOSAGE STUDY 
I ,t3 * * IM B t~ (p) ClB Vd(B) D.* D * 
-1 l m µg/ml) (min ) (min) (ml/min/kg) (ml/kg) (mg/kg) (ml/kg) 
2.51 0.0007 946.27 0.2915 397.98 4.78 3.92 
2.49 0.0010 718.16 0.3880 402.09 4.82 4.07 
2.77 0.0008 817.28 0.3058 360.64 4.33 3.53 
3.14 0.0008 809.45 0.2729 318.77 3.82 3.18 
3.54 0.0009 745.65 0.2365 254.48 3.06 2.52 
3.37 0.0011 653.18 0.3467 326.78 3.92 3.31 
2.00 0.0009 756.68 0.4589 501. 05 6.01 4.98 
3.31 0.0013 538.01 0.3889 301. 89 3.62 3.03 
2.57 0.0010 665.09 o. 44F.':\ 428.37 5.14 4.22 
I 2.86 0.0009 538.86 0.3484 365.78 4.39 3.64 
I 0.51 0.0002 116.22 0.0777 74.83 0.90 0.74 
T* 
(hr) 
40.77 
30.94 
35.21 
34.87 
32.12 
28.14 
32.60 
23.18 
28.65 
31.83 
5.01 
<..D 
I-' 
Catfish 
I. D. 
TABLE XVI 
(Continued) 
* * IM 
B !Cl t~(JS) ClB vd(B) Di* Dm* 
(µg/ml) (min- 1 ) (min) (ml/min/kg) (ml/kg) (mg/kg) (ml/kg) 
r 
(hr) 
Value Calculated 
from Table XVI B 
and J8 Values 
770.16 0.3182 353.54 4.24 3.54 33.18 
t Calculated 
* v -d(area) -
* - IM 
from Vd(area)I~ather than Vd(B); 
Vd(area) " Vd(B) = 2.65.79 ml/kg 
Vd(B) 
(3.19t) (2.66t) 
t..O 
N 
TABLE XVII 
CALCULATED PLASMA GENTAMICIN CONCENTRATIONS AT 
GIVEN TIME INTERVALS AFTER INTRAMUSCULAR 
DOSE ADMINISTRATION 
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Catfish Dose c240min c360min c480min C 720mincl_440min I.D. p p p p p 
(mg/kg) (µg/ml) (µg/ml) (fig/ml) (µg/ml) (µg/ml) 
E2Cl 1. 0 2.11 1. 93 1. 77 1.48 0.88 
E2C2 1. 0 1. 97 1. 76 1.56 1.24 0.62 
E2C3 1.0 2.26 2.04 1. 84 1. 50 0.82 
E2C4 1. 0 2.55 2.30 2.08 1. 69 0.91 
E2C5 0.9 2.83 2.53 2.26 1. 81 0.93 
E2C6 1.1 2.61 2.30 2.02 1. 57 0.73 
E2C7 1. 0 1. 60 1.44 1. 28 1.03 0.53 
E2C8 1. 0 2.43 2.08 1. 78 1. 31 0.52 
E2C9 1.1 2.00 1. 76 1. 56 1. 21 0.57 
Mean 1. 01 2.26 2.02 . 1. 79 1.43 0.72 Value 
Standard 0.06 0.38 0.34 0.30 0.25 0 .17 Deviation 
Value Calculated 
from Table XVI 2.30 2.07 1. 86 1.50 0.78 
Mean Values 
TABLE XVIII 
GENTAMICIN WATER CONCENTRATIONS EXTRAPOLATED FROM 
TANK DOSAGE STUDY RAW DATA 
Group of Catfish Regression Line Deve- Corre- Gentamicin Concentration 
Exposed to Tank loped from Water Assay lation (..ug/ml) at t= 
Dosage Raw Data Coeffi- 240 360 480 720 
cient 
min min min min 
E3Cl 
-1 d=log ( -0. 00007 ( t) +8,Ug/ml) 0.31 7.7 7.6 7.4 7.1 
E3C2' E3C3' 
-1 d=log (-0.000l(t)+8.4pg/ml) 0.29 8.0 7.8 7.6 7.2 
E3C4 
E3C5, E3C6, 
-1 d=log (-0.00002(t)+7.3,.tfg/ml)0.09 7.25 7.22 7.2 7.1 
E3C7 
E3C8' E3c9 , 
-1 . . d=log (-0.00002(t)+6.5flg/ml)0.15 6.5 6.4 6.4 6.3 
E3Cl0 
d = gentamicin tank dose in;<.g/ml 
t = time in minutes 
1440 
min 
6.3 
6.2 
7.0 
6.1 
\.0 
.i::. 
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